JP
TEVA icon

John Paulson’s Teva Pharmaceuticals TEVA Stock Holding History

John Paulson’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,450,000
Closed -$43.1M – 59
2017
Q3 		$43.1M Sell
2,450,000
-4,294,000
-64% -$96.6M 0.77% 25
2017
Q2 		$224M Sell
6,744,000
-4,253,300
-39% -$132M 3.03% 12
2017
Q1 		$353M Sell
10,997,300
-4,928,500
-31% -$168M 4.68% 5
2016
Q4 		$577M Sell
15,925,800
-151,100
-0.9% -$6.03M 7.28% 4
2016
Q3 		$740M Sell
16,076,900
-696,900
-4% -$36.4M 8.02% 4
2016
Q2 		$843M Sell
16,773,800
-3,828,400
-19% -$204M 8.56% 4
2016
Q1 		$1.1B Buy
20,602,200
+192,900
+0.9% +$11.3M 8.15% 3
2015
Q4 		$1.34B Buy
20,409,300
+2,409,300
+13% +$149M 8.01% 4
2015
Q3 		$1.02B Buy
18,000,000
+15,969,500
+786% +$1.04B 5.28% 6
2015
Q2 		$120M Buy
+2,030,500
New +$125M 0.55% 31

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

John Paulson's TEVA Position: Q4 2017 in Review

John Paulson sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 2,450,000 shares — an estimated $43.1M sold.

John Paulson first reported a position in TEVA in Q2 2015 and held it in 10 quarters. The position peaked at $1.34B in Q4 2015. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • John Paulson reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • John Paulson sold 2,450,000 Teva Pharmaceuticals shares in Q4 2017, an estimated $43.1M.
  • John Paulson first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 10 quarters.
  • John Paulson's Teva Pharmaceuticals position peaked at $1.34B in Q4 2015.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Paulson & Co's 13F filing for Q4 2017, filed 14 Feb 2018.